Editorial Article

Ninety-Three Compounding Plants and a Corridor That Closes

Updated November 18, 2026

The most sophisticated sterile compounding in the United States is not happening in a hospital. It is happening in ninety-three buildings, and their licence to operate is narrower than almost anyone outside the sector assumes.

The FDA registered 97 outsourcing facilities in fiscal 2025. Four of them paid the fee, registered, and then withdrew before the year ended. On the last day of the fiscal year, 93 were registered. The agency collected USD 2,219,440 in outsourcing facility fees, which funded seven full-time equivalents — a fraction of the total oversight effort, as its own report to Congress concedes.

That is the 503B sector: about seventy-six facilities in 2019, roughly forty in 2014, ninety-three now. Steady, modest, mature growth. And behind the number is a rule that determines everything about how those buildings are equipped.

The corridor

An outsourcing facility may compound copies of an approved drug only while that drug is on the FDA’s shortage list. When the shortage is declared resolved, compounding has to stop after a limited transition period — regardless of whether access has actually normalised at the hospital level.

That is not a technicality. It is the entire commercial basis of the category. The semaglutide episode of 2024 and 2025 is the clearest recent illustration: compounded supply expanded access while the shortage persisted, and then had to stop when it was removed from the list, despite continuing affordability and access problems. A facility that had built capacity against that demand owned assets with a use-by date set by a regulatory decision it did not control.

The scale of the corridor is measurable. Comparative work on FDA shortage lists and 503B production data suggests that fewer than 20 per cent of the active pharmaceutical ingredients in shortage overlap meaningfully with what outsourcing facilities compound at scale. The reason is not capacity. It is chemistry and regulation. Oncology agents, biologics, complex injectables and narrow-therapeutic-index products are not suitable for compounding at scale — the formulation complexity, the stability requirements or the regulatory constraints rule them out. What remains compoundable is a narrower band of older, off-patent sterile injectables with straightforward formulations and high hospital demand: analgesics, vasopressors, anaesthetics, electrolytes.

So the sector functions as a clinical shock absorber. It has genuinely kept procedures running during acute disruptions. It has not reduced the number, duration or recurrence of shortages, and on its current perimeter it cannot.

What that does to the capital

If your demand window can be closed by a regulatory listing decision, you do not buy the same automation a contract manufacturer buys. Our interviews with vendors selling into this layer describe a consistent pattern, and it is the most useful thing in this corner of the market.

503B operators buy automation that can be repurposed across products, and they buy it with a short validation cycle. The underwrite is two to three years, not the seven to ten a hospital uses. Throughput matters, but flexibility matters more, because the product mix can change twice inside an asset’s useful life. Vendors who sell on filling speed alone lose to vendors who sell on changeover time — which is the opposite of the pitch that works in a hospital pharmacy.

That behaviour explains a number that otherwise looks strange. The 503B and central-fill batch automation layer is USD 158 million in 2025, growing 9.09 per cent to USD 317 million by 2033. It grows, and it grows slower than every other layer in the market, and it loses share from 16.8 per cent to 11.5 per cent. A sector with ninety-three facilities and a permanent structural role, growing at single-digit rates while the hospital market compounds at 14.37 per cent.

Why hospitals still automate their own cleanrooms

The strategic mistake is to read 503B growth as a substitution threat to the hospital cleanroom. It is not, and the arithmetic says so.

Roughly a third of US hospitals use no technology of any kind for sterile compounding. Of 6,093 hospitals, 225 use any automation for the process and 177 use a robot. Ninety-three outsourcing facilities cannot absorb the preparation volume of six thousand hospitals, and they are legally barred from compounding most of what those hospitals actually need. What they can do is take the shortage-driven, high-volume, simple-formulation work — which is precisely the work a hospital cleanroom would otherwise have to scale up for, temporarily, during a supply disruption.

That is a real relief, and it is relief of a specific kind: it removes the peaks. And removing the peaks is quietly bearish for automation in the short run, because a lot of hospital compounding capital is justified by peak capacity — the surge requirement that forces a room to be bigger or faster than its average day requires. A hospital that can hand the peak to a 503B partner has less reason to buy the machine.

Which is why the hospital market’s growth does not come from shortage management at all. It comes from compliance, labour and consolidation.

The compliance floor moved, and it moved toward documentation

The revised USP chapter <797>, official since 1 November 2023, removed the permission to prepare a low volume of hazardous drugs outside a negative pressure space and required two tiers of containment. It made the designated person(s) accountable for the facility, the personnel and the process. It tied preparation classification to environmental monitoring rather than to intent.

None of that requires a robot. All of it requires a record. And a record is the one thing a validated system produces better than a person with a clipboard — which is why the verification layer, not the robotic layer, is the fastest-growing part of this market at 16.52 per cent and the only layer that gains share.

The stranded-asset question nobody underwrites

Here is the risk that the sector’s growth numbers hide. The 503B business model carries a demand risk that is not competitive and not operational — it is administrative. A facility that finances an automated line against a shortage window is making a bet on how long a regulator takes to resolve a supply problem it does not control.

Hospitals make the same bet from the other side when they sign an outsourcing agreement: they are buying continuity that can be withdrawn. The sensible response, and the one we see in the larger systems, is to treat 503B as redundancy rather than as replacement — which is exactly the framing that preserves the in-house cleanroom and, with it, the case for automating it.

What it means for the next eight years

The 503B channel will keep growing and will keep being a corridor. Ninety-three facilities is not a platform from which to stabilise a national injectable supply chain, and the economics of low-margin generics do not support building one. The facilities that do well will be the ones whose portfolios have decoupled from the shortage cycle — ready-to-use presentations, customised formulations, convenience products — because those are the products that do not disappear when a shortage is declared over.

For the automation market, the consequence is a modest, fast-cycling batch layer growing at 9.09 per cent and a hospital layer growing at 14.37 per cent that is driven by rooms, compliance and consolidation, not by outsourcing. The two markets touch at the technology frontier — batch capability developed for a 503B line gets cheaper and migrates into health-system central fill, and only then into the individual hospital room — and that migration, not the facility count, is the thing worth watching.

The full analysis of both channels, including the layer splits, the regulatory boundary and the sensitivity of the forecast to its weakest assumption, is in Global IV Sterile Compounding Automation Market Report, Size, Share and Forecast 2026–2033.

Frequently Asked Questions

What is a 503B outsourcing facility?

A 503B outsourcing facility is a compounding facility registered with the FDA under the Drug Quality and Security Act of 2013. It may compound drugs without patient-specific prescriptions and may compound copies of approved products only while those products are on the FDA shortage list, under cGMP rather than state pharmacy rules.

How many 503B facilities are registered?

The FDA registered 97 in fiscal 2025, of which four withdrew before the year ended, leaving 93 registered on the last day of the fiscal year. That compares with roughly 76 in 2019 and about 40 in 2014. The agency collected USD 2,219,440 in outsourcing facility fees in the year.

Why haven't 503B facilities solved US drug shortages?

Because fewer than 20 per cent of the active ingredients in shortage overlap meaningfully with what outsourcing facilities can compound at scale. Oncology agents, biologics, complex injectables and narrow-therapeutic-index drugs are excluded by formulation complexity, stability requirements or regulation, so the sector relieves specific shortages rather than the shortage problem.

Does 503B outsourcing reduce hospital compounding volume?

Not much, though it removes the peaks. A hospital that can hand surge demand to a 503B partner has less reason to buy peak capacity in its own cleanroom, but the routine preparation volume, the compliance requirement and the labour economics all remain. That is why the hospital automation market grows on compliance, labour and consolidation rather than on shortage management.